{"id":"polidocanol","rwe":[{"pmid":"41884965","year":"2026","title":"Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.","finding":"","journal":"The Journal of dermatological treatment","studyType":"Clinical Study"},{"pmid":"41873145","year":"2026","title":"Long-term follow-up of sclerotherapy of telangiectasias and reticular veins in lower limbs: Glucose versus polidocanol diluted in glucose.","finding":"","journal":"Vascular medicine (London, England)","studyType":"Clinical Study"},{"pmid":"41872773","year":"2026","title":"Laparoscopic polidocanol foam sclerotherapy for retroperitoneal lymphatic malformations in children: a single center retrospective study.","finding":"","journal":"BMC pediatrics","studyType":"Clinical Study"},{"pmid":"41861582","year":"2026","title":"Clinical Outcomes of Polidocanol Foam Sclerotherapy in Treatment of Sublingual Ranula.","finding":"","journal":"International dental journal","studyType":"Clinical Study"},{"pmid":"41851558","year":"2026","title":"Polidocanol in Sclerotherapy for Lymphovenous Disorders: Mechanisms, Clinical Uses, and Future Prospects.","finding":"","journal":"Drugs","studyType":"Clinical Study"}],"_fda":{"id":"f443bbaf-ef8e-4f9e-ba4c-6f87dc58a671","set_id":"bb1f342b-5352-4059-a0b2-e60fd652fd28","openfda":{"nui":["N0000175814","N0000020024","N0000009905"],"upc":["0367850141056","0367850140059"],"unii":["0AWH8BFG9A"],"route":["INTRAVENOUS"],"rxcui":["968173","968177","968181","968183"],"spl_id":["f443bbaf-ef8e-4f9e-ba4c-6f87dc58a671"],"brand_name":["Asclera"],"spl_set_id":["bb1f342b-5352-4059-a0b2-e60fd652fd28"],"package_ndc":["67850-141-05","67850-140-05"],"product_ndc":["67850-140","67850-141"],"generic_name":["POLIDOCANOL"],"product_type":["HUMAN PRESCRIPTION DRUG"],"pharm_class_pe":["Vascular Sclerosing Activity [PE]"],"substance_name":["POLIDOCANOL"],"pharm_class_epc":["Sclerosing Agent [EPC]"],"pharm_class_moa":["Sclerosing Activity [MoA]"],"manufacturer_name":["Methapharm, Inc"],"application_number":["NDA021201"],"is_original_packager":[true]},"version":"26","pregnancy":["8.1 Pregnancy Risk Summary The available data from case reports on use of polidocanol-containing products, including ASCLERA, in pregnant women have not identified any drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes. Although none of these risks have been identified, there is minimal benefit in treating uncomplicated spider veins and reticular veins in the lower extremity during pregnancy and lower extremity varicosities that develop during pregnancy as they may spontaneously regress postpartum. The animal reproduction studies were conducted in a manner to achieve systemic exposure, while the intended clinical use is local exposure at the injection site with minimal to no systemic exposure; therefore, these data are not relevant to the intended clinical use (see Data ) . The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data Developmental reproductive toxicity testing was performed in rats and rabbits with intravenous administration. Polidocanol induced maternal and fetal toxicity in rabbits, including reduced mean fetal weight and reduced fetal survival, when administered during gestation days 6-20 at doses of 4 and 10 mg/kg, but it did not cause skeletal or visceral abnormalities. No adverse maternal or fetal effects were observed in rabbits at a dose of 2 mg/kg. No evidence of teratogenicity or fetal toxicity was observed in rats dosed during gestation days 6-17 with doses up to 10 mg/kg. Polidocanol did not affect the ability of rats to deliver and rear pups when administered intermittently by intravenous injection from gestation day 17 to post-partum day 21 at doses up to 10 mg/kg. These studies were conducted in a manner to achieve systemic exposure, while the intended clinical use is local exposure at the injection site with minimal to no systemic exposure; therefore, these data are not relevant to the intended clinical use."],"overdosage":["10 OVERDOSAGE Overdose may result in a higher incidence of localized reactions such as necrosis."],"description":["11 DESCRIPTION Asclera is a sterile, nonpyrogenic, and colorless to faintly greenish-yellow solution of polidocanol for intravenous use as a sclerosing agent. The active ingredient, polidocanol is a non-ionic detergent, consisting of two components, a polar hydrophilic (dodecyl alcohol) and an apolar hydrophobic (polyethylene oxide) chain. Polidocanol has the following structural formula: C 12 H 25 (OCH 2 CH 2 ) n OH Polyethylene glycol monododecyl ether Mean extent of polymerization (n) : Approximately 9 Mean molecular weight : Approximately 600 Each mL contains 5 mg (0.5%) or 10 mg (1.0%) polidocanol in water for injection with 5% (v/v) ethanol at pH 6.5-8.0; disodium hydrogen phosphate dihydrate (1.2 mg), potassium dihydrogen phosphate (0.43 mg). chemical structure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Asclera (polidocanol) injection is a colorless to faintly greenish-yellow solution supplied in single-dose, sterile, preservative free ampules in the following packages: NDC 67850-140-05 Five 0.5 % ampules [10 mg/2 mL (5 mg/mL)] NDC 67850-141-05 Five 1 % ampules [20 mg/2 mL (10 mg/mL)] Each ampule is intended for immediate use in a single patient. Each unopened ampule is stable up to three years. Store at 15°C to 30°C; (59°F to 86°F)."],"geriatric_use":["8.5 Geriatric Use Clinical studies of Asclera did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of Asclera in pediatric patients have not been established."],"effective_time":"20250716","clinical_studies":["14 CLINICAL STUDIES Asclera was evaluated in a multicenter, randomized, double-blind, placebo- and comparator-controlled trial (EASI-study) in patients with spider or reticular varicose veins. A total of 338 patients were treated with Asclera [0.5% for spider veins (n=94), 1% for reticular veins (n=86)], sodium tetradecyl sulfate (STS) 1% (n=105), or placebo (0.9% isotonic saline solution) (n=53) for either spider or reticular veins. Patients were predominately female, ranging in age from 19 to 70 years. All of them received an intravenous injection in the first treatment session; repeat injections were given three and six weeks later if the previous injection was evaluated as unsuccessful (defined as 1, 2 or 3 on a 5-point scale, see below). Patients returned at 12 and 26 weeks after the last injection for final assessments. The primary effectiveness endpoint was improvement of veins judged by a blinded panel. Digital images of the selected treatment area were taken prior to injection, compared with those taken at 12 weeks post-treatment, and rated on a 5-point scale (1 = worse than before, 2 = same as before, 3 = moderate improvement, 4 = good improvement, 5 = complete treatment success); results are shown in Table 2. Table 2: Improvement of veins in digital photographs after 12 weeks and 26 weeks Treatment Group Polidocanol (n=155) STS (n=105) Placebo (n=53) Digital Photograph Scores at 12 weeks Mean ± SD 4.5 p <0.0001 compared to placebo (Wilcoxon-Mann-Whitney test) ± 0.7 4.5 ± 0.7 2.2 ± 0.7 Digital Photograph Scores at 26 weeks Mean ± SD 4.5 ± 0.7 4.5 ± 0.8 2.2 ± 0.7 The secondary efficacy criterion was the rate of treatment success, pre-defined as a score of 4 or 5 with patients scoring 1, 2, or 3 considered treatment failures; results are shown in Table 3. Table 3: Treatment success rates at 12 weeks and 26 weeks Treatment Success Treatment success: Yes= Grade 4 to 5, No= Grade 1 to 3; derived from median of evaluation; Polidocanol (n=155) STS (n=105) Placebo (n=53) At 12 weeks (Visit 4) Yes 95% p<0.0001 compared to placebo. 92% 8% No 5% 8% 92% Missing 0.6% 0% 0% At 26 weeks (Visit 5) Yes 95% 91% 6% No 5% 9% 94% At 12 and 26 weeks, patients' judgement of the results was assessed by showing them the digital images of their treatment area taken at baseline and asking them to rate their satisfaction with their treatment using a verbal rating scale (1 = very unsatisfied; 2 = somewhat unsatisfied; 3 = slightly satisfied; 4 = satisfied and 5 = very satisfied); results are shown in Table 4. Table 4: Patient satisfaction after 12 weeks and 26 weeks Polidocanol (N=155) STS (N=105) Placebo (N=53) Patient satisfaction with treatment after 12 weeks (Visit 4) Satisfied or very satisfied 87% p <0.0001 compared to STS and placebo 64% 14% Patient satisfaction with treatment after 26 weeks (Visit 5) Satisfied or very satisfied 84% 63% 16%"],"pharmacodynamics":["12.2 Pharmacodynamics Polidocanol has a concentration- and volume-dependent damaging effect on the endothelium of blood vessels."],"pharmacokinetics":["12.3 Pharmacokinetics During the major effectiveness study (EASI-trial), scheduled blood samples were taken from a sub-group of 22 patients to measure plasma levels of polidocanol after Asclera treatment of spider and reticular veins. Low systemic blood levels of polidocanol were seen in some patients. The mean t 1/2 of polidocanol in 4 patients with evaluable data receiving 4.5 -18.0 mg was 1.5 h."],"adverse_reactions":["6 ADVERSE REACTIONS The most common adverse reactions occurring at least 3% more frequently than on placebo are mild local reactions at the site of injection. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Methapharm at 1-866-701-4636 or medinfo@methapharm.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Study Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. In 5 controlled randomized clinical trials, Asclera has been administered to 401 patients with small or very small varicose veins (reticular and spider veins) and compared with another sclerosing agent and with placebo. Patients were 18 to 70 years old. The patient population was predominately female and consisted of Caucasian and Asian patients. Table 1 shows adverse events more common with Asclera or sodium tetradecyl sulfate (STS) 1% than with placebo by at least 3% in the placebo-controlled EASI study [see Clinical Studies (14) ] . All of these were injection site reactions and most were mild. Table 1: Adverse Reactions in EASI-study ASCLERA (180 patients) STS 1% (105 patients) Placebo (53 patients) Injection site haematoma 42% 65% 19% Injection site irritation 41% 73% 30% Injection site discoloration 38% 74% 4% Injection site pain 24% 31% 9% Injection site pruritus 19% 27% 4% Injection site warmth 16% 21% 6% Neovascularisation 8% 20% 4% Injection site thrombosis 6% 1% 0% Ultrasound examinations at one week (±3 days) and 12 weeks (±2 weeks) after treatment did not reveal deep vein thrombosis in any treatment group. 6.2 Post-marketing Safety Experience The following adverse reactions have been reported during use of polidocanol in world-wide experience. Because these reactions are reported voluntarily from a population of uncertain size and without a control group, it is not possible to estimate their frequency reliably or to establish a causal relationship to drug exposure. Immune system disorders: Anaphylactic shock, angioedema, urticaria generalized, asthma Nervous system disorders: Cerebrovascular accident, migraine, paresthesia (local), loss of consciousness, confusional state, dizziness Cardiac disorders: Cardiac arrest, palpitations Vascular disorders: Deep vein thrombosis, pulmonary embolism, syncope vasovagal, circulatory collapse, vasculitis Respiratory, thoracic and mediastinal disorders: Dyspnea Skin and subcutaneous tissue disorders : Skin hyperpigmentation, dermatitis allergic, hypertrichosis (in the area of sclerotherapy) General disorders and injection site conditions : Injection site necrosis, pyrexia, hot flush Injury, poisoning and procedural complications : Nerve injury"],"contraindications":["4 CONTRAINDICATIONS Asclera is contraindicated for patients with known allergy to polidocanol and patients with acute thromboembolic diseases. Known allergies to polidocanol. ( 4 ) Patients with acute thromboembolic diseases. ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS No drug-drug interactions have been studied with Asclera."],"mechanism_of_action":["12.1 Mechanism of Action The active ingredient of Asclera is polidocanol. Polidocanol is a sclerosing agent that locally damages the endothelium of blood vessels. When injected intravenously, polidocanol induces endothelial damage. Platelets then aggregate at the site of damage and attach to the venous wall. Eventually, a dense network of platelets, cellular debris, and fibrin occludes the vessel. Finally, the occluded vein is replaced with connective fibrous tissue."],"storage_and_handling":["Store at 15°C to 30°C; (59°F to 86°F)."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action The active ingredient of Asclera is polidocanol. Polidocanol is a sclerosing agent that locally damages the endothelium of blood vessels. When injected intravenously, polidocanol induces endothelial damage. Platelets then aggregate at the site of damage and attach to the venous wall. Eventually, a dense network of platelets, cellular debris, and fibrin occludes the vessel. Finally, the occluded vein is replaced with connective fibrous tissue. 12.2 Pharmacodynamics Polidocanol has a concentration- and volume-dependent damaging effect on the endothelium of blood vessels. 12.3 Pharmacokinetics During the major effectiveness study (EASI-trial), scheduled blood samples were taken from a sub-group of 22 patients to measure plasma levels of polidocanol after Asclera treatment of spider and reticular veins. Low systemic blood levels of polidocanol were seen in some patients. The mean t 1/2 of polidocanol in 4 patients with evaluable data receiving 4.5 -18.0 mg was 1.5 h."],"indications_and_usage":["1 INDICATIONS AND USAGE Asclera ® (polidocanol) is indicated to sclerose uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity. Asclera has not been studied in varicose veins more than 3 mm in diameter. Asclera (polidocanol) is a sclerosing agent indicated to sclerose uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity. Asclera has not been studied in varicose veins more than 3mm in diameter. ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Be prepared to treat anaphylaxis. ( 5.1 ) Venous Thrombosis and Pulmonary Embolism. ( 5.2 ) Arterial Embolism. ( 5.3 ) Tissue ischemia and necrosis: Do not inject intra-arterially. ( 5.4 ) 5.1 Anaphylaxis Severe allergic reactions have been reported following polidocanol use, including anaphylactic reactions, some of them fatal. Severe reactions are more frequent with use of larger volumes (> 3 mL). Minimize the dose of polidocanol. Be prepared to treat anaphylaxis appropriately. Severe adverse local effects, including tissue necrosis, may occur following extravasation; therefore, take care in intravenous needle placement and use the smallest effective volume at each injection. After the injection session is completed, apply compression with a stocking or bandage, and have the patient walk for 15-20 minutes. Keep the patient under supervision during this period to treat any anaphylactic or allergic reaction [see Dosage and Administration (2) ] . 5.2 Venous Thrombosis and Pulmonary Embolism Asclera can cause venous thrombosis and subsequent pulmonary embolism or other thrombotic events. Follow administration instructions closely and monitor for signs of venous thrombosis after treatment. Patients with reduced mobility, history of deep vein thrombosis or pulmonary embolism, or recent (within 3 months) major surgery, prolonged hospitalization or pregnancy are at increased risk for developing thrombosis. 5.3 Arterial Embolism Stroke, transient ischemic attack, myocardial infarction, and impaired cardiac function have been reported in close temporal relationship with polidocanol administration. These events may be caused by air embolism when using the product foamed with room air (high nitrogen concentration) or thromboembolism. The safety and efficacy of polidocanol foamed with room air has not been established and its use should be avoided. 5.4 Tissue Ischemia and Necrosis Intra-arterial injection or extravasation of polidocanol can cause severe necrosis, ischemia or gangrene. Take care in intravenous needle placement and use the smallest effective volume at each injection site. After the injection session is completed, apply compression with a stocking or bandage and have patients walk for 15-20 minutes. If intra-arterial injection of polidocanol occurs, consult a vascular surgeon immediately."],"clinical_studies_table":["
Table 2: Improvement of veins in digital photographs after 12 weeks and 26 weeks
Treatment GroupPolidocanol (n=155)STS (n=105)Placebo (n=53)
Digital Photograph Scores at 12 weeks
Mean ± SD4.5p <0.0001 compared to placebo (Wilcoxon-Mann-Whitney test) ± 0.74.5± 0.72.2 ± 0.7
Digital Photograph Scores at 26 weeks
Mean ± SD4.5 ± 0.74.5± 0.82.2 ± 0.7
","
Table 3: Treatment success rates at 12 weeks and 26 weeks
Treatment SuccessTreatment success: Yes= Grade 4 to 5, No= Grade 1 to 3; derived from median of evaluation; Polidocanol (n=155)STS (n=105)Placebo (n=53)
At 12 weeks (Visit 4)
Yes 95%p<0.0001 compared to placebo.92%8%
No 5%8%92%
Missing 0.6%0%0%
At 26 weeks (Visit 5)
Yes 95%91%6%
No 5%9%94%
","
Table 4: Patient satisfaction after 12 weeks and 26 weeks
Polidocanol (N=155)STS (N=105)Placebo (N=53)
Patient satisfaction with treatment after 12 weeks (Visit 4)
Satisfied or very satisfied87%p <0.0001 compared to STS and placebo64%14%
Patient satisfaction with treatment after 26 weeks (Visit 5)
Satisfied or very satisfied84%63%16%
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term studies to evaluate carcinogenic potential have not been conducted with polidocanol. Polidocanol was negative in bacterial reverse mutation assays in Salmonella and E. coli, and in a micronucleus assay conducted in mice. Polidocanol induced numerical chromosomal aberrations in cultured newborn Chinese hamster lung fibroblasts in the absence of metabolic activation. Polidocanol did not affect reproductive performance (fertility) of rats when administered intermittently at dosages up to 10 mg/kg (approximately equal to the maximum human dose on the basis of body surface area)."],"adverse_reactions_table":["
Table 1: Adverse Reactions in EASI-study
ASCLERA (180 patients)STS 1% (105 patients)Placebo (53 patients)
Injection site haematoma42%65%19%
Injection site irritation41%73%30%
Injection site discoloration38%74%4%
Injection site pain24%31%9%
Injection site pruritus19%27%4%
Injection site warmth16%21%6%
Neovascularisation8%20%4%
Injection site thrombosis6%1%0%
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to wear compression stockings or support hose on the treated legs continuously for 2 to 3 days and for 2 to 3 weeks during the daytime. Compression stockings or support hose should be thigh or knee high depending upon the area treated in order to provide adequate coverage. Advise the patient to walk for 15 to 20 minutes immediately after the procedure and daily for the next few days. For two to three days following treatment, advise the patient to avoid heavy exercise, sunbathing, long plane flights, and hot baths or sauna. Distributed by: Methapharm, Inc. Boca Raton, FL 33433 Tel: 1-833-766-8346 www.asclera.com Manufactured by: Chemische Fabrik Kreussler & Co. GmbH 65203 Wiesbaden GERMANY Asclera is a registered trademark of Chemische Fabrik Kreussler & Co. GmbH, 65203 Wiesbaden, GERMANY"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION For intravenous use only. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if particulate matter is seen or if the contents of the vial are discolored or if the vial is damaged in any way. For spider veins (varicose veins ≤1 mm in diameter), use Asclera 0.5%. For reticular veins (varicose veins 1 to 3 mm in diameter), use Asclera 1%. Use 0.1 to 0.3 mL per injection and no more than 10 mL per session. Use a syringe (glass or plastic) with a fine needle (typically, 26- or 30-gauge). Insert the needle tangentially into the vein and inject the solution slowly while the needle is still in the vein. Apply only gentle pressure during injection to prevent vein rupture. After the needle has been removed and the injection site has been covered, apply compression in the form of a stocking or bandage. After the treatment session, encourage the patient to walk for 15 to 20 minutes. Keep the patient under observation to detect any anaphylactic or allergic reaction [see Warnings and Precautions (5.3) ] . Maintain compression for 2 to 3 days after treatment of spider veins and for 5 to 7 days for reticular veins. For extensive varicosities, longer compression treatment with compression bandages or a gradient compression stocking of a higher compression class is recommended. Post-treatment compression is necessary to reduce the risk of deep vein thrombosis. Repeat treatments may be necessary if the extent of the varicose veins requires more than 10 mL. These treatments should be separated by 1 to 2 weeks. Small intravaricose thrombi that develop may be removed by microthrombectomy. For intravenous use only. Solution strength and the volume injected depend on the size and extent of the varicose veins. Extensive varicosities may require multiple treatment sessions. ( 2 ) Spider veins (varicose veins ≤1 mm in diameter): Use Asclera 0.5%. ( 2 ) Reticular veins (varicose veins 1 to 3 mm in diameter): Use Asclera 1%. ( 2 ) Use 0.1 to 0.3 mL for each injection into each varicose vein. The maximum recommended volume per treatment session is 10 mL. ( 2 )"],"spl_product_data_elements":["Asclera POLIDOCANOL POLIDOCANOL POLIDOCANOL ALCOHOL MONOBASIC POTASSIUM PHOSPHATE SODIUM PHOSPHATE, DIBASIC, UNSPECIFIED FORM WATER Asclera POLIDOCANOL POLIDOCANOL POLIDOCANOL ALCOHOL MONOBASIC POTASSIUM PHOSPHATE SODIUM PHOSPHATE, DIBASIC, UNSPECIFIED FORM WATER"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Asclera (polidocanol) is an injection for intravenous use and is available as follows: • 0.5% [10 mg/2 mL (5 mg/mL)] solution in 2 mL single-dose glass ampule • 1% [20 mg/2 mL (10 mg/mL)] solution in 2 mL single-dose glass ampule 0.5% and 1% solution in 2 mL glass ampules. ( 3 )"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary The available data from case reports on use of polidocanol-containing products, including ASCLERA, in pregnant women have not identified any drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes. Although none of these risks have been identified, there is minimal benefit in treating uncomplicated spider veins and reticular veins in the lower extremity during pregnancy and lower extremity varicosities that develop during pregnancy as they may spontaneously regress postpartum. The animal reproduction studies were conducted in a manner to achieve systemic exposure, while the intended clinical use is local exposure at the injection site with minimal to no systemic exposure; therefore, these data are not relevant to the intended clinical use (see Data ) . The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Animal Data Developmental reproductive toxicity testing was performed in rats and rabbits with intravenous administration. Polidocanol induced maternal and fetal toxicity in rabbits, including reduced mean fetal weight and reduced fetal survival, when administered during gestation days 6-20 at doses of 4 and 10 mg/kg, but it did not cause skeletal or visceral abnormalities. No adverse maternal or fetal effects were observed in rabbits at a dose of 2 mg/kg. No evidence of teratogenicity or fetal toxicity was observed in rats dosed during gestation days 6-17 with doses up to 10 mg/kg. Polidocanol did not affect the ability of rats to deliver and rear pups when administered intermittently by intravenous injection from gestation day 17 to post-partum day 21 at doses up to 10 mg/kg. These studies were conducted in a manner to achieve systemic exposure, while the intended clinical use is local exposure at the injection site with minimal to no systemic exposure; therefore, these data are not relevant to the intended clinical use. 8.2 Lactation Risk Summary There are no data on the presence of polidocanol in human milk, the effects on the breastfed infant, or the effects on milk production. A lactating woman may consider interrupting breastfeeding and pumping and discarding breast milk up to 8 hours after ASCLERA administration in order to minimize exposure to a breastfed infant. 8.4 Pediatric Use The safety and effectiveness of Asclera in pediatric patients have not been established. 8.5 Geriatric Use Clinical studies of Asclera did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects."],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 20 mg Ampule Carton NDC 67850-141-05 ASCLERA ® (polidocanol) Injection 20 mg per 2 mL (10 mg per mL) 1% For Intravenous Use Only Rx Only Single use: Discard unused portion Contains: 5 ampules each containing 20 mg per 2 mL PRINCIPAL DISPLAY PANEL - 20 mg Ampule Carton","PRINCIPAL DISPLAY PANEL - 10 mg Ampule Carton NDC 67850-140-05 ASCLERA ® (polidocanol) Injection 10 mg per 2 mL (5 mg per mL) 0.5% For Intravenous Use Only Rx Only Single use: Discard unused portion Contains: 5 ampules each containing 10 mg per 2 mL PRINCIPAL DISPLAY PANEL - 10 mg Ampule Carton"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Long-term studies to evaluate carcinogenic potential have not been conducted with polidocanol. Polidocanol was negative in bacterial reverse mutation assays in Salmonella and E. coli, and in a micronucleus assay conducted in mice. Polidocanol induced numerical chromosomal aberrations in cultured newborn Chinese hamster lung fibroblasts in the absence of metabolic activation. Polidocanol did not affect reproductive performance (fertility) of rats when administered intermittently at dosages up to 10 mg/kg (approximately equal to the maximum human dose on the basis of body surface area)."]},"tags":[{"label":"Sclerosing Agent","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"C05BB02","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Injection","category":"form"},{"label":"LOE Approaching","category":"status"},{"label":"Venous varices","category":"indication"},{"label":"Provensis","category":"company"},{"label":"Approved 2010s","category":"decade"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Detergents","category":"pharmacology"},{"label":"Pharmaceutical Solutions","category":"pharmacology"},{"label":"Sclerosing Solutions","category":"pharmacology"},{"label":"Surface-Active Agents","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DEEP VEIN THROMBOSIS","source":"FDA FAERS","actionTaken":"337 reports"},{"date":"","signal":"NO ADVERSE EVENT","source":"FDA FAERS","actionTaken":"93 reports"},{"date":"","signal":"PAIN","source":"FDA FAERS","actionTaken":"84 reports"},{"date":"","signal":"PAIN IN EXTREMITY","source":"FDA FAERS","actionTaken":"68 reports"},{"date":"","signal":"PRODUCT QUALITY ISSUE","source":"FDA FAERS","actionTaken":"65 reports"},{"date":"","signal":"WRONG TECHNIQUE IN PRODUCT USAGE PROCESS","source":"FDA FAERS","actionTaken":"62 reports"},{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"56 reports"},{"date":"","signal":"ERYTHEMA","source":"FDA FAERS","actionTaken":"52 reports"},{"date":"","signal":"SKIN DISCOLOURATION","source":"FDA FAERS","actionTaken":"50 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"42 reports"}],"commonSideEffects":[{"effect":"Injection site haematoma","drugRate":"42%","severity":"serious","_validated":true},{"effect":"Injection site irritation","drugRate":"41%","severity":"serious","_validated":true},{"effect":"Injection site discoloration","drugRate":"38%","severity":"serious","_validated":true},{"effect":"Injection site pain","drugRate":"24%","severity":"common","_validated":true},{"effect":"Injection site pruritus","drugRate":"19%","severity":"common","_validated":true},{"effect":"Injection site warmth","drugRate":"16%","severity":"common","_validated":true},{"effect":"Neovascularisation","drugRate":"8%","severity":"mild","_validated":true},{"effect":"Injection site thrombosis","drugRate":"6%","severity":"mild","_validated":true},{"effect":"Immune system disorders: Anaphylactic shock","drugRate":"reported","severity":"unknown"},{"effect":"Immune system disorders: Angioedema","drugRate":"reported","severity":"unknown"},{"effect":"Immune system disorders: Urticaria generalized","drugRate":"reported","severity":"unknown"},{"effect":"Immune system disorders: Asthma","drugRate":"reported","severity":"unknown"},{"effect":"Nervous system disorders: Cerebrovascular accident","drugRate":"reported","severity":"unknown"},{"effect":"Nervous system disorders: Migraine","drugRate":"reported","severity":"unknown"},{"effect":"Nervous system disorders: Paresthesia (local)","drugRate":"reported","severity":"unknown"},{"effect":"Nervous system disorders: Loss of consciousness","drugRate":"reported","severity":"unknown"},{"effect":"Nervous system disorders: Confusional state","drugRate":"reported","severity":"unknown"},{"effect":"Nervous system disorders: Dizziness","drugRate":"reported","severity":"unknown"},{"effect":"Cardiac disorders: Cardiac arrest","drugRate":"reported","severity":"unknown"},{"effect":"Cardiac disorders: Palpitations","drugRate":"reported","severity":"unknown"},{"effect":"Vascular disorders: Deep vein thrombosis","drugRate":"reported","severity":"unknown"},{"effect":"Vascular disorders: Pulmonary embolism","drugRate":"reported","severity":"unknown"},{"effect":"Vascular disorders: Syncope vasovagal","drugRate":"reported","severity":"unknown"},{"effect":"Vascular disorders: Circulatory collapse","drugRate":"reported","severity":"unknown"},{"effect":"Vascular disorders: Vasculitis","drugRate":"reported","severity":"unknown"},{"effect":"Respiratory, thoracic and mediastinal disorders: Dyspnea","drugRate":"reported","severity":"unknown"},{"effect":"Skin and subcutaneous tissue disorders: Skin hyperpigmentation","drugRate":"reported","severity":"unknown"},{"effect":"Skin and subcutaneous tissue disorders: Dermatitis allergic","drugRate":"reported","severity":"unknown"},{"effect":"Skin and subcutaneous tissue disorders: Hypertrichosis (in the area of sclerotherapy)","drugRate":"reported","severity":"unknown"},{"effect":"General disorders and injection site conditions: Injection site necrosis","drugRate":"reported","severity":"unknown"}],"specialPopulations":{"Lactation":"There are no data on the presence of polidocanol in human milk, the effects on the breastfed infant, or the effects on milk production. lactating woman may consider interrupting breastfeeding and pumping and discarding breast milk up to hours after ASCLERA administration in order to minimize exposure to breastfed infant.","Pregnancy":"The available data from case reports on use of polidocanol-containing products, including ASCLERA, in pregnant women have not identified any drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes. Although none of these risks have been identified, there is minimal benefit in treating uncomplicated spider veins and reticular veins in the lower extremity during pregnancy and lower extremity varicosities that develop during pregnancy as they may spontaneously regress postpartum. The animal reproduction studies were conducted in manner to achieve systemic exposure, while the intended clinical use is local exposure at the injection site with minimal to no systemic exposure; therefore, these data are not relevant to the intended clinical use (see Data). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is to 4% and 15 to 20%, respectively.. Data. Animal DataDevelopmental reproductive toxicity testing was performed in rats and rabbits with intravenous administration. Polidocanol induced maternal and fetal toxicity in rabbits, including reduced mean fetal weight and reduced fetal survival, when administered at doses that produced systemic exposure.","Geriatric use":"Clinical studies of Asclera did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.","Paediatric use":"The safety and effectiveness of Asclera in pediatric patients have not been established."}},"trials":[],"aliases":["lauromacrogol 400","lauromacrogol"],"company":"Provensis","patents":[{"applNo":"N205098","source":"FDA Orange Book","status":"Active","expires":"Nov 19, 2027","useCode":"U-1461","territory":"US","drugProduct":true,"patentNumber":"7814943","drugSubstance":false},{"applNo":"N205098","source":"FDA Orange Book","status":"Active","expires":"May 12, 2032","useCode":"","territory":"US","drugProduct":true,"patentNumber":"9480652","drugSubstance":false}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=POLIDOCANOL","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:05:18.605996+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T03:05:18.605612+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:05:25.033348+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T03:05:16.947667+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=POLIDOCANOL","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:05:25.807915+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:05:15.665505+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:05:15.665653+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:05:15.665683+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T03:05:30.826994+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL6067961/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:05:26.289913+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA021201","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T03:05:15.665694+00:00"}},"allNames":"asclera","offLabel":[],"synonyms":["polidocanol","asclera","varithena","Laureth-9","polyethylene glycol monododecyl ether","aethoxysklerol"],"timeline":[{"date":"2010-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from CHEMISCH FBRK KRSSLR to Provensis"},{"date":"2010-03-30","type":"positive","source":"DrugCentral","milestone":"FDA approval (Chemisch Fbrk Krsslr)"}],"aiSummary":"Asclera (polidocanol) is a sclerosing agent used to treat venous varices. It is a small molecule modality originally developed by Chemisch FBRK Krsslr and currently owned by Provensis. Asclera works by causing inflammation and scarring in the targeted veins, leading to their closure. It was FDA-approved in 2010 and remains a branded product. Key safety considerations include potential allergic reactions and nerve damage.","approvals":[{"date":"2010-03-30","orphan":false,"company":"CHEMISCH FBRK KRSSLR","regulator":"FDA"}],"brandName":"Asclera","ecosystem":[{"indication":"Venous varices","otherDrugs":[{"name":"sodium tetradecyl sulfate","slug":"sodium-tetradecyl-sulfate","company":"Elkins Sinn"}],"globalPrevalence":null}],"mechanism":{"novelty":"Follow-on","moaClass":"Sclerosing Activity","modality":"Small Molecule","drugClass":"Sclerosing Agent [EPC]","explanation":"The active ingredient of Asclera is polidocanol.Polidocanol is sclerosing agent that locally damages the endothelium of blood vessels. When injected intravenously, polidocanol induces endothelial damage. Platelets then aggregate at the site of damage and attach to the venous wall. Eventually, dense network of platelets, cellular debris, and fibrin occludes the vessel. Finally, the occluded vein is replaced with connective fibrous tissue.","oneSentence":"Asclera works by causing inflammation and scarring in targeted veins, leading to their closure.","technicalDetail":"Asclera (polidocanol) is a detergent-like sclerosing agent that disrupts the endothelial cell membrane, leading to cell lysis, inflammation, and subsequent fibrosis, resulting in vein closure."},"commercial":{"launchDate":"2010","_launchSource":"DrugCentral (FDA 2010-03-30, CHEMISCH FBRK KRSSLR)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4614","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=POLIDOCANOL","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=POLIDOCANOL","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T15:22:13.823356","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:05:36.007863+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"ethanolamine oleate","drugSlug":"ethanolamine-oleate","fdaApproval":"1988-12-22","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"sodium tetradecyl sulfate","drugSlug":"sodium-tetradecyl-sulfate","fdaApproval":"1946-08-13","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"phenol","drugSlug":"phenol","fdaApproval":"","relationship":"same-class"},{"drugName":"glucose","drugSlug":"glucose","fdaApproval":"1946-01-17","relationship":"same-class"}],"genericName":"polidocanol","indications":{"approved":[{"name":"Venous varices","source":"DrugCentral","snomedId":128060009,"regulator":"FDA","eligibility":"Uncomplicated spider veins (varicose veins <=1 mm in diameter) and uncomplicated reticular veins (varicose veins to 3mm in diameter) in the lower extremity. No age or stage restrictions mentioned, but varicose veins more than 3mm in diameter have not been studied."}],"offLabel":[],"pipeline":[]},"currentOwner":"Provensis","drugCategory":"loe-approaching","labelChanges":[],"relatedDrugs":[{"drugId":"ethanolamine-oleate","brandName":"ethanolamine oleate","genericName":"ethanolamine oleate","approvalYear":"1988","relationship":"same-class"},{"drugId":"sodium-tetradecyl-sulfate","brandName":"sodium tetradecyl sulfate","genericName":"sodium tetradecyl sulfate","approvalYear":"1946","relationship":"same-class"},{"drugId":"phenol","brandName":"phenol","genericName":"phenol","approvalYear":"","relationship":"same-class"},{"drugId":"glucose","brandName":"glucose","genericName":"glucose","approvalYear":"1946","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05312970","phase":"PHASE4","title":"Varithena Versus Endothermal Ablation of the Great Saphenous Vein (VERITAS)","status":"TERMINATED","sponsor":"Boston Scientific Corporation","startDate":"2023-02-10","conditions":["Varicose Veins"],"enrollment":43,"completionDate":"2024-04-04"},{"nctId":"NCT07445425","phase":"NA","title":"Comparison of Radiofrequency Ablation With Concomitant or Staged Treatment for Tributary Varicose Veins","status":"NOT_YET_RECRUITING","sponsor":"Sir Run Run Shaw Hospital","startDate":"2026-03","conditions":["Varicose Veins of Lower Limb"],"enrollment":206,"completionDate":"2026-12"},{"nctId":"NCT03041805","phase":"","title":"Caprini Score in Venous Surgery: a Prospective Cohort Study","status":"RECRUITING","sponsor":"Pirogov Russian National Research Medical University","startDate":"2017-01-01","conditions":["Venous Thromboembolism","Varicose Veins"],"enrollment":3000,"completionDate":"2027-01-01"},{"nctId":"NCT07320430","phase":"NA","title":"Comparative Study Between Sclerosing Agents Used in Treatment of Vascular Malformation","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2024-02-14","conditions":["Vascular Malformation"],"enrollment":75,"completionDate":"2025-08-15"},{"nctId":"NCT07307131","phase":"PHASE2","title":"Furosemide-Digoxin vs. Polidocanol for Cutaneous Warts","status":"COMPLETED","sponsor":"Benha University","startDate":"2024-09-01","conditions":["Cutaneous Warts","Human Papilloma Virus (HPV)"],"enrollment":64,"completionDate":"2025-09-30"},{"nctId":"NCT07276243","phase":"NA","title":"Polidocanol Foam With or Without Transdermal Laser for Varicose Veins: Randomized Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"Hospital Universitario Pedro Ernesto","startDate":"2026-01-01","conditions":["Varicose Veins"],"enrollment":102,"completionDate":"2027-12-30"},{"nctId":"NCT06667570","phase":"NA","title":"Efficacy of the SALFOAM 3% Method Compared to the Conventional Polidocanol Foam Method (Tessari Method) for Treating Lower Limb Varicose Veins","status":"COMPLETED","sponsor":"Lidiane Rocha","startDate":"2024-10-25","conditions":["Varicose Veins"],"enrollment":35,"completionDate":"2025-02-14"},{"nctId":"NCT06132165","phase":"PHASE1","title":"Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2024-03-01","conditions":["Neurofibromatosis 1"],"enrollment":13,"completionDate":"2025-07-31"},{"nctId":"NCT07221695","phase":"NA","title":"Embolization Strategies for Pelvic Venous Disorders: Foam + Glue vs Foam + Coils","status":"ENROLLING_BY_INVITATION","sponsor":"Kafrelsheikh University","startDate":"2025-08-25","conditions":["Pelvic Congestive Syndrome"],"enrollment":60,"completionDate":"2025-12-25"},{"nctId":"NCT07162844","phase":"NA","title":"Foam and Liquid Sclerotherapy With or Without Herbal Gel for Small Vein Treatment","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2024-09-05","conditions":["Telangectasia","Reticular Veins"],"enrollment":508,"completionDate":"2025-09-01"},{"nctId":"NCT07073742","phase":"PHASE2","title":"CLaCS Using 0.2% Aetoxysklerol Foam and 70% Glucose for the Treatment of Lower Limb Telangiectasias","status":"NOT_YET_RECRUITING","sponsor":"Charles University, Czech Republic","startDate":"2025-09-01","conditions":["Varicose Veins of Lower Limb","Spider Veins","Reticular Leg Veins"],"enrollment":240,"completionDate":"2028-09-01"},{"nctId":"NCT02557542","phase":"NA","title":"Pilot RCT Evaluating a One Stop Vein Clinic","status":"TERMINATED","sponsor":"Imperial College London","startDate":"2015-10","conditions":["Varicose Veins"],"enrollment":3,"completionDate":"2021-03"},{"nctId":"NCT06962813","phase":"NA","title":"Transdermal Radiofrequency V ERASER Versus Polidocanol Sclerotherapy for Reticular Veins and Telangiectasias","status":"COMPLETED","sponsor":"Science Valley Research Institute","startDate":"2023-01-10","conditions":["Varicose Veins Leg","Telangiectasias"],"enrollment":46,"completionDate":"2025-04-10"},{"nctId":"NCT06120036","phase":"PHASE1","title":"Dosing and Tolerability of Deoxycholic Acid vs. Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2022-12-06","conditions":["Neurofibromatosis 1"],"enrollment":20,"completionDate":"2025-01-09"},{"nctId":"NCT06175754","phase":"NA","title":"Laser Treatment of Reticular Leg Veins Vs. Sclerotherapy","status":"RECRUITING","sponsor":"Derzhavin Tambov State University","startDate":"2023-10-09","conditions":["Reticular Leg Veins"],"enrollment":174,"completionDate":"2025-12-09"},{"nctId":"NCT06749665","phase":"NA","title":"Sclerotherapy and Candida Antigen in Treatment of Common Warts","status":"NOT_YET_RECRUITING","sponsor":"Sohag University","startDate":"2024-12-20","conditions":["Common Wart"],"enrollment":75,"completionDate":"2025-12-01"},{"nctId":"NCT06318988","phase":"","title":"Outcomes of Different Treatment Options in Chronic Venous Disease","status":"NOT_YET_RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2024-07-01","conditions":["Chronic Venous Disease"],"enrollment":2000,"completionDate":"2027-05-01"},{"nctId":"NCT02154789","phase":"PHASE4","title":"An Assessment of Intra-lesional 3% Polidocanol Solution in the Treatment of Digital Myxoid Cyst","status":"TERMINATED","sponsor":"University of Edinburgh","startDate":"2015-07-27","conditions":["Ganglion Cysts"],"enrollment":10,"completionDate":"2015-10-01"},{"nctId":"NCT06399744","phase":"NA","title":"Role of Sclerotherapy in Treatment of Non-neoplastic Ovarian Cyst","status":"COMPLETED","sponsor":"Al-Azhar University","startDate":"2022-09-01","conditions":["Benign Ovarian Cyst"],"enrollment":52,"completionDate":"2024-02-28"},{"nctId":"NCT04258761","phase":"PHASE2","title":"A Safety and Tolerability Study of 10XB-101 Injections in Adult Subjects With Extra Fat Under the Chin (\"Double Chin\")","status":"COMPLETED","sponsor":"10xBio, LLC","startDate":"2019-10-10","conditions":["Submental Fat"],"enrollment":15,"completionDate":"2022-08-31"},{"nctId":"NCT06122467","phase":"NA","title":"A Single Group Study to Evaluate the Efficacy of a Cosmetic Product Line on Acne Symptoms","status":"COMPLETED","sponsor":"Menning Labs","startDate":"2023-10-02","conditions":["Acne"],"enrollment":36,"completionDate":"2023-12-31"},{"nctId":"NCT06311669","phase":"NA","title":"Comparative Study Between Isolated Iliac Vein Stenting Versus Concomitant Iliac Vein Stenting With Pelvic Vein Embolization in Patients With Pelvic Venous Insufficiency Secondary to Nonthrombotic Iliac Vein Lesions","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2024-03-01","conditions":["Nonthrombotic Iliac Vein Lesions","Pelvic Congestive Syndrome"],"enrollment":20,"completionDate":"2025-03"},{"nctId":"NCT06192472","phase":"NA","title":"Investigation Into the Pathophysiology and Treatment of Varicose Veins","status":"COMPLETED","sponsor":"University of Surrey","startDate":"2013-04","conditions":["Varicose Veins"],"enrollment":120,"completionDate":"2015-09"},{"nctId":"NCT05860439","phase":"","title":"Lower Limb Sclerotherapy of Reticular Veins and Telangiectasias","status":"COMPLETED","sponsor":"UPECLIN HC FM Botucatu Unesp","startDate":"2017-01-01","conditions":["Telangiectasis"],"enrollment":191,"completionDate":"2023-06-01"},{"nctId":"NCT06031740","phase":"NA","title":"A Comparison of Flexible Endoscopic Polidocanol Liquid and Foam Sclerotherapy in Cirrhotic Patients With Bleeding From Internal Hemorrhoids","status":"UNKNOWN","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2023-09-07","conditions":["Liver Cirrhosis","Internal Hemorrhoid"],"enrollment":60,"completionDate":"2024-08-31"},{"nctId":"NCT05807425","phase":"PHASE2,PHASE3","title":"Polidocanol Foam in Hemorrhoidal Disease in Patients With Liver Cirrhosis","status":"UNKNOWN","sponsor":"Universidade do Porto","startDate":"2023-03-31","conditions":["Hemorrhoids","Liver Cirrhosis"],"enrollment":40,"completionDate":"2023-12-31"},{"nctId":"NCT05798936","phase":"PHASE4","title":"Comparative Study of Polidocanol and Absolute Alcohol for Percutaneous us Guided Treatment of Benign Thyroid Cyst","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-04-01","conditions":["Benign Thyroid Nodule","Thyroid Lump","Thyroid Cyst"],"enrollment":30,"completionDate":"2025-06-01"},{"nctId":"NCT05633277","phase":"NA","title":"Outcomes of Sclerotherapy of the Ulcer Bed Compared to a Combination of Ablation and Injections","status":"UNKNOWN","sponsor":"ProMedica Health System","startDate":"2020-09-30","conditions":["Venous Reflux","Venous Insufficiency","Venous Ulcer","Venous Disease"],"enrollment":30,"completionDate":"2024-03"},{"nctId":"NCT05586919","phase":"NA","title":"Treatment of Venous Malformation","status":"COMPLETED","sponsor":"Al-Azhar University","startDate":"2018-10-01","conditions":["Venous Malformation"],"enrollment":20,"completionDate":"2021-03-01"},{"nctId":"NCT05566093","phase":"NA","title":"EUS-FNI for Nonfunctional Pancreatic Neuroendocrine Tumors","status":"UNKNOWN","sponsor":"Guangxi Medical University","startDate":"2018-09-28","conditions":["Nonfunctional Pancreatic Neuroendocrine Tumor","Pancreatic Neuroendocrine Tumor","Endoscopic Ultrasound"],"enrollment":20,"completionDate":"2025-12-31"},{"nctId":"NCT05554744","phase":"NA","title":"EUS-FNI for MEN1-related Pancreatic Neuroendocrine Tumors","status":"UNKNOWN","sponsor":"Guangxi Medical University","startDate":"2015-06-18","conditions":["Multiple Endocrine Neoplasia Type 1","Pancreatic Neuroendocrine Tumor"],"enrollment":20,"completionDate":"2025-12"},{"nctId":"NCT05500625","phase":"NA","title":"Endoscopic Ultrasound-guided Coil With Cyanoacrylate Injection Versus Balloon-Occluded Retrograde Transvenous Obliteration in Managing Patients With Gastric Varices","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2022-08-30","conditions":["Gastric Varix"],"enrollment":70,"completionDate":"2025-01-30"},{"nctId":"NCT05468450","phase":"NA","title":"RCT Comparing EVLA Versus Polidocanol Foam in the Treatment of SSV Insufficiency","status":"COMPLETED","sponsor":"Societe Francaise de Phlebologie","startDate":"2015-07-01","conditions":["Varicose Veins of Lower Limb"],"enrollment":161,"completionDate":"2016-08-31"},{"nctId":"NCT03754140","phase":"PHASE2","title":"Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases","status":"WITHDRAWN","sponsor":"Melanoma Institute Australia","startDate":"2020-05-20","conditions":["Melanoma","In-Transit Metastasis of Cutaneous Melanoma"],"enrollment":0,"completionDate":"2022-12"},{"nctId":"NCT05228054","phase":"NA","title":"Treatment of Hemorrhoid With 1940nm Laser Procedure","status":"UNKNOWN","sponsor":"State Scientific Centre of Coloproctology, Russian Federation","startDate":"2021-01-26","conditions":["Hemorrhoids"],"enrollment":200,"completionDate":"2024-08-30"},{"nctId":"NCT05165043","phase":"","title":"Position Changes in Cirrhosis Hemorrhagic Spot Detection","status":"UNKNOWN","sponsor":"Ningbo No. 1 Hospital","startDate":"2021-12-30","conditions":["Emergency Hemostasis"],"enrollment":11,"completionDate":"2022-01-30"},{"nctId":"NCT03257254","phase":"","title":"Effect of VarIthena on Wound Healing in Venous Leg Ulcers (VLU)","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2017-09-29","conditions":["Venous Leg Ulcer"],"enrollment":76,"completionDate":"2020-09-28"},{"nctId":"NCT02468180","phase":"NA","title":"Primary Prophylaxis of Gastric Variceal Bleed","status":"UNKNOWN","sponsor":"West China Hospital","startDate":"2015-06","conditions":["Gastric Varices"],"enrollment":70,"completionDate":"2022-07"},{"nctId":"NCT03791775","phase":"PHASE2","title":"Efficacy and Safety of Polidocanol Foam 3% in the Treatment of II Degree Hemorrhoidal Disease","status":"COMPLETED","sponsor":"Societa Italiana di Chirurgia ColoRettale","startDate":"2019-01-02","conditions":["Second-degree Hemorrhoids"],"enrollment":183,"completionDate":"2020-06-02"},{"nctId":"NCT00928421","phase":"PHASE2","title":"An Open-label, Single-dose Pilot Study to Evaluate Varisolve® (Polidocanol Endovenous Microfoam (PEM)) 0.125% [0.2%] for Varicose Veins","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2009-06","conditions":["Varicose Veins"],"enrollment":16,"completionDate":"2010-01"},{"nctId":"NCT04846361","phase":"NA","title":"Vaginal Hygiene Wash as Adjunct Treatment in Bacterial Vaginosis","status":"UNKNOWN","sponsor":"Universiti Kebangsaan Malaysia Medical Centre","startDate":"2021-05","conditions":["Bacterial Vaginoses"],"enrollment":56,"completionDate":"2022-01"},{"nctId":"NCT01072877","phase":"PHASE3","title":"Efficacy and Safety Study of Polidocanol Injectable Foam for the Treatment of Saphenofemoral Junction (SFJ) Incompetence","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2010-12","conditions":["Varicose Veins"],"enrollment":279,"completionDate":"2012-11"},{"nctId":"NCT00442364","phase":"PHASE2","title":"Safety Study of Varisolve® Procedure for Treatment of Varicose Veins in Patients With Right-to-left Cardiac Shunt","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2007-03","conditions":["Varicose Veins"],"enrollment":60,"completionDate":"2009-08"},{"nctId":"NCT01428076","phase":"PHASE1","title":"Pharmacokinetic Study of Polidocanol Endovenous Microfoam (PEM)","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2011-08","conditions":["Varicose Veins"],"enrollment":21,"completionDate":"2012-01"},{"nctId":"NCT02462720","phase":"PHASE4","title":"COMFORT: A Multicenter, Open-label, Randomized, Crossover Study","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2015-05","conditions":["Varicose Veins"],"enrollment":35,"completionDate":"2016-03"},{"nctId":"NCT00758420","phase":"PHASE2,PHASE3","title":"Randomized, Single Blind, Placebo Controlled, to Evaluate Efficacy and Safety of Polidocanol Injectable Foam for Treatment of Symptomatic, Visible Varicose Veins With SFJ Incompetence","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2008-10","conditions":["Varicose Veins"],"enrollment":77,"completionDate":"2009-08"},{"nctId":"NCT01231373","phase":"PHASE3","title":"Polidocanol Endovenous Microfoam (PEM) Versus Vehicle for the Treatment of Saphenofemoral Junction (SFJ) Incompetence","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2010-11","conditions":["Varicose Veins"],"enrollment":235,"completionDate":"2014-08"},{"nctId":"NCT01197833","phase":"PHASE3","title":"Endovenous Ablation With and Without Polidocanol Endovenous Microfoam Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities","status":"COMPLETED","sponsor":"Boston Scientific Corporation","startDate":"2010-09","conditions":["Great Saphenous Vein Incompetence","Visible Varicosities"],"enrollment":117,"completionDate":"2012-12"},{"nctId":"NCT04675177","phase":"PHASE2,PHASE3","title":"Polidocanol Foam VS Artery Ligation in Hemorrhoidal Disease","status":"COMPLETED","sponsor":"Universidade do Porto","startDate":"2019-09-01","conditions":["Hemorrhoids"],"enrollment":45,"completionDate":"2020-03-25"},{"nctId":"NCT04091763","phase":"PHASE2","title":"Polidocanol Foam Versus Rubber Band Ligation in the Treatment of Hemorrhoidal Disease","status":"COMPLETED","sponsor":"Universidade do Porto","startDate":"2018-08-01","conditions":["Hemorrhoids, Internal"],"enrollment":120,"completionDate":"2020-07-01"},{"nctId":"NCT04188171","phase":"PHASE2,PHASE3","title":"Sclerotherapy With Polidocanol Foam In The Treatment Of Hemorrhoidal Disease In Patients With Bleeding Disorders","status":"UNKNOWN","sponsor":"Universidade do Porto","startDate":"2018-08-01","conditions":["Hemorrhoids","Bleeding Disorder"],"enrollment":150,"completionDate":"2021-02-01"},{"nctId":"NCT04398823","phase":"PHASE4","title":"A Multicenter Prospective Clinical Study of Endoscopic Foam Sclerotherapy for Internal Hemorrhoids","status":"UNKNOWN","sponsor":"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2020-05-15","conditions":["Grade/Stage I Hemorrhoids","Prolapsed Grade II Internal Haemorrhoid","Prolapsed Grade III Internal Haemorrhoid"],"enrollment":700,"completionDate":"2021-12-31"},{"nctId":"NCT04358497","phase":"PHASE4","title":"Endovascular Versus Medical Treatment for the Pelvic Congestion Syndrome","status":"UNKNOWN","sponsor":"Hospital de Clínicas Dr. Manuel Quintela","startDate":"2020-10-01","conditions":["Pelvic Congestive Syndrome","Pelvic Varices","Venous Disease"],"enrollment":120,"completionDate":"2022-10-01"},{"nctId":"NCT02468206","phase":"NA","title":"Secondary Prophylaxis of Gastric Variceal Bleed","status":"COMPLETED","sponsor":"West China Hospital","startDate":"2015-06","conditions":["Gastric Varices"],"enrollment":64,"completionDate":"2019-01-07"},{"nctId":"NCT02468167","phase":"NA","title":"Acute Gastric Variceal Bleeding: Endoscopic Treatment Versus BRTO","status":"UNKNOWN","sponsor":"West China Hospital","startDate":"2015-06","conditions":["Gastric Varices"],"enrollment":70,"completionDate":"2020-07"},{"nctId":"NCT03043534","phase":"NA","title":"Pre-Shave Gel and Brush in Pseudofolliculitis Barbae","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2015-11-12","conditions":["Pseudofolliculitis Barbae"],"enrollment":29,"completionDate":"2016-10-12"},{"nctId":"NCT03326219","phase":"NA","title":"Endoveneous Histologic Study","status":"WITHDRAWN","sponsor":"Rijnstate Hospital","startDate":"2017-01","conditions":["Varicose Veins"],"enrollment":0,"completionDate":"2020-12"},{"nctId":"NCT03729921","phase":"NA","title":"Gastric Variceal Ligation Versus Gastric Variceal Obturation for Secondary Prophylaxis of Gastric Varices","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2018-11","conditions":["Gastroesophageal Varices","Liver Cirrhosis"],"enrollment":166,"completionDate":"2020-06"},{"nctId":"NCT00843466","phase":"NA","title":"Compatibility of a Mild, Moisturizing Hand Cleanser for Patients With Mild to Moderate Hand Dermatitis","status":"COMPLETED","sponsor":"Wake Forest University","startDate":"2007-05","conditions":["Hand Dermatosis"],"enrollment":46,"completionDate":"2008-11"},{"nctId":"NCT02657252","phase":"PHASE4","title":"Polidocanol Versus Glucose Treatment of Telangiectasia Trial","status":"COMPLETED","sponsor":"UPECLIN HC FM Botucatu Unesp","startDate":"2015-01","conditions":["Varicose Veins","Telangiectasis"],"enrollment":115,"completionDate":"2016-11"},{"nctId":"NCT02753270","phase":"NA","title":"Catheter-directed Foam Sclerotherapy With Tumescence","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2014-12","conditions":["Varicose Vein of Lower Limbs"],"enrollment":50,"completionDate":"2017-04"},{"nctId":"NCT02988063","phase":"PHASE4","title":"Effect of PEM Treatment of Superficial Axial and Tributary Vein Reflux on Improvement of Wound Healing in VLUs","status":"WITHDRAWN","sponsor":"OhioHealth","startDate":"2017-04-10","conditions":["Leg Ulcer","Veins, Varicose","Venous Ulcer","Reflux","Venous Reflux","Venous Leg Ulcer","Varicose Veins","Varicose Ulcer","Varicose Veins Leg"],"enrollment":0,"completionDate":"2017-09-12"},{"nctId":"NCT02054325","phase":"PHASE4","title":"Study Protocol Comparing Polidocanol Versus Hypertonic Glucose for Treatment of Reticular Veins","status":"COMPLETED","sponsor":"UPECLIN HC FM Botucatu Unesp","startDate":"2012-09","conditions":["Varicose Veins"],"enrollment":106,"completionDate":"2014-12"},{"nctId":"NCT02361593","phase":"NA","title":"Transparent Cap-assisted Endoscopic Sclerotherapy","status":"COMPLETED","sponsor":"Shanghai Zhongshan Hospital","startDate":"2015-04","conditions":["Esophageal Varices"],"enrollment":120,"completionDate":"2016-12"},{"nctId":"NCT02082613","phase":"NA","title":"Lord´s Procedure Versus Sclerotherapy for Testicular Hydrocele; a Randomized Controlled Study","status":"UNKNOWN","sponsor":"Umeå University","startDate":"2015-02","conditions":["Testicular Hydrocele"],"enrollment":200,"completionDate":"2017-04"},{"nctId":"NCT01923064","phase":"NA","title":"Injection of Cyanoacrylate+Lipiodol vs Cyanoacrylate+Lauromacrogol in Gastric Varices","status":"COMPLETED","sponsor":"Shanghai Zhongshan Hospital","startDate":"2013-10","conditions":["Gastric Varices","Portal Hypertension"],"enrollment":96,"completionDate":"2013-12"},{"nctId":"NCT01898182","phase":"PHASE4","title":"Efficacy and Safety of Kinetin 0.1% for Treatment of Skin Photoaging","status":"COMPLETED","sponsor":"Makati Medical Center","startDate":"2013-11","conditions":["Cutaneous Photoaging"],"enrollment":132,"completionDate":"2014-09"},{"nctId":"NCT00377910","phase":"PHASE4","title":"The Efficacy of Polidocanol Injections as a Treatment of Chronic Achilles. Tendinopathy","status":"COMPLETED","sponsor":"Northern Orthopaedic Division, Denmark","startDate":"2008-03","conditions":["Chronic Achilles Tendinopathy"],"enrollment":48,"completionDate":"2009-01"},{"nctId":"NCT00621062","phase":"NA","title":"Prospective Randomized Trial Comparing the New Endovenous Procedures Versus Conventional Surgery for Varicose Veins Due to Great Saphenous Vein Incompetence","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2008-01","conditions":["Varicose Veins"],"enrollment":540,"completionDate":"2014-01"},{"nctId":"NCT02010723","phase":"PHASE4","title":"Surgery Versus Sclerotherapy for Isolated Accessory Great Saphenous Vein Varicosis","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2006-06","conditions":["Varicose Veins"],"enrollment":40,"completionDate":"2012-02"},{"nctId":"NCT00529672","phase":"PHASE3","title":"Surgery or Noninvasive Therapy for Varicose Veins","status":"UNKNOWN","sponsor":"Erasmus Medical Center","startDate":"2007-05","conditions":["Varicose Vein"],"enrollment":240,"completionDate":"2011-05"},{"nctId":"NCT01185951","phase":"PHASE2","title":"TENDOSHOCK-2010 Combination Therapy for Athletic Tendinopathies","status":"UNKNOWN","sponsor":"Hannover Medical School","startDate":"2007-01","conditions":["Tendinopathy","Epicondylitis"],"enrollment":114,"completionDate":"2010-12"},{"nctId":"NCT00399451","phase":"PHASE1,PHASE2","title":"Polidocanol Sclerotherapy of Pharynges for Obstructive Sleep Apnea (OSA) and Snoring Subjects(SS)","status":"UNKNOWN","sponsor":"Liaoyang Central Hospital","startDate":"2006-12","conditions":["Apnea","Snoring"],"enrollment":30,"completionDate":"2009-06"},{"nctId":"NCT00348764","phase":"PHASE3","title":"ESGVS: Sclerotherapy With Lauromacrogol","status":"COMPLETED","sponsor":"University Hospital, Grenoble","startDate":"2004-03","conditions":["Venous Insufficiency","Saphenous Vein"],"enrollment":150,"completionDate":"2006-12"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Injection","formulations":[{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Asclera"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000184324","MMSL":"185389","NDDF":"006261","UNII":"0AWH8BFG9A","VUID":"4031333","CHEBI":"CHEBI:46859","VANDF":"4018563","INN_ID":"1562","RXNORM":"1484399","UMLSCUI":"C0071330","chemblId":"CHEMBL6067961","ChEMBL_ID":"CHEMBL1231723","KEGG_DRUG":"D01993","DRUGBANK_ID":"DB06811","PUBCHEM_CID":"656641","SNOMEDCT_US":"427905004","MESH_DESCRIPTOR_UI":"D000077423"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2010-","companyName":"Chemisch Fbrk Krsslr","relationship":"Original Developer"},{"period":"present","companyName":"Provensis","relationship":"Current Owner"}],"publicationCount":1077,"therapeuticAreas":["Hematology"],"atcClassification":{"source":"DrugCentral","atcCode":"C05BB02","allCodes":["C05BB02"]},"biosimilarFilings":[],"originalDeveloper":"Chemisch Fbrk Krsslr","recentPublications":[{"date":"2026 Dec","pmid":"41884965","title":"Local therapeutic strategies for neurocutaneous dysesthesia: from capsaicin to cannabinoids.","journal":"The Journal of dermatological treatment"},{"date":"2026 Mar 23","pmid":"41873145","title":"Long-term follow-up of sclerotherapy of telangiectasias and reticular veins in lower limbs: Glucose versus polidocanol diluted in glucose.","journal":"Vascular medicine (London, England)"},{"date":"2026 Mar 23","pmid":"41872773","title":"Laparoscopic polidocanol foam sclerotherapy for retroperitoneal lymphatic malformations in children: a single center retrospective study.","journal":"BMC pediatrics"},{"date":"2026 Mar 19","pmid":"41861582","title":"Clinical Outcomes of Polidocanol Foam Sclerotherapy in Treatment of Sublingual Ranula.","journal":"International dental journal"},{"date":"2026 Mar 18","pmid":"41851558","title":"Polidocanol in Sclerotherapy for Lymphovenous Disorders: Mechanisms, Clinical Uses, and Future Prospects.","journal":"Drugs"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Provensis","companyId":"provensis","modality":"Small molecule","firstApprovalDate":"2010","enrichmentLevel":3,"visitCount":2,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2010-03-30T00:00:00.000Z","mah":"CHEMISCH FBRK KRSSLR","brand_name_local":null,"application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2017-12-21T00:00:00.000Z","mah":"PROVENSIS","brand_name_local":null,"application_number":"NDA205098"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2018-03-01T00:00:00.000Z","mah":"CHEMISCH FBRK KRSSLR","brand_name_local":null,"application_number":"NDA021201"},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":3,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:05:36.007863+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}